Related references
Note: Only part of the references are listed.Cytotoxic CD8+T cells in cancer and cancer immunotherapy
Hans Raskov et al.
BRITISH JOURNAL OF CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
Landon C. Brown et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
Chundi Gao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis
Manlio Mencoboni et al.
CANCERS (2021)
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
Sandra van Wilpe et al.
CANCERS (2021)
Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer
Yuan Qiu et al.
FRONTIERS IN ONCOLOGY (2021)
FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
Zixin Guo et al.
FRONTIERS IN ONCOLOGY (2021)
Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.
Dominique Berton et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeting macrophages in cancer immunotherapy
Zhaojun Duan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Tumor-infiltrating lymphocytes in the immunotherapy era
Sterre T. Paijens et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
J. Nicholas Bodor et al.
CANCER (2020)
Microsatellite instability: a review of what the oncologist should know
Kai Li et al.
CANCER CELL INTERNATIONAL (2020)
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen et al.
NATURE GENETICS (2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
J. H. Shim et al.
ANNALS OF ONCOLOGY (2020)
KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
J. R. Brahmer et al.
ANNALS OF ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
Hao Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
LBA78IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
D Spigel et al.
ANNALS OF ONCOLOGY (2019)
PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin
Qiang Ma et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Galactan isolated from Cantharellus cibarius modulates antitumor immune response by converting tumor-associated macrophages toward M1-like phenotype
Yue Meng et al.
CARBOHYDRATE POLYMERS (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Clinicopathological characteristics of&IT POLE&IT mutation in patients with non-small-cell lung cancer
Zhengbo Song et al.
LUNG CANCER (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.
Mohamed E. Salem et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation
J. Nicholas Bodor et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel
Kazuya Takamochi et al.
LUNG CANCER (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Function and cancer genomics of FAT family genes (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein
CX Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
